drugset / Trial / NCT03503331

UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

NCT03503331

NaSingle-groupOpen-labelDiagnostic

Summary

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.

Timeline

Start
2018-04-20
Primary completion
2028-10
Completion
2028-10

Drugs

EvaluationDrugModalityDoseRoute
Subject C-11 PiB Diagnostic / imaging agent 300 mbq Intravenous
Subject C-11 PiB Diagnostic / imaging agent 670 mbq Intravenous

Indications